Dr. Lee received his Bachelor degree in Chemical Engineering and Master degree in Radiation Biology from National Tsing Hua University in Taiwan and PhD degree in Cancer Biology from the University Of Texas Graduate School Of Biomedical Sciences at Houston. In 2016 after completing the post-doctoral training in the Black Family Stem Cell Institute at Icahn School of Medicine at Mount Sinai, Dr. Lee joined the Department of Integrative Biology and Pharmacology, and the Center for Stem Cell and Regenerative Medicine at the University of Texas Health Science Center at Houston as an Assistant Professor. Dr. Lee is the first person applying iPSC disease model to study familial cancer syndrome. Currently, Dr. Lee is the CPRIT scholar in Cancer Research.
The Lee laboratory is dedicated to understand cancer pathological mechanisms by using patient-specific iPSCs and/or engineered ESCs. The Lee laboratory has established the first human Li-Fraumeni syndrome (LFS) disease model by using LFS patient-specific iPSCs to delineate the pathological mechanisms caused by mutant p53 in osteosarcoma. The Lee laboratory continues to apply TALENs and CRISPR/Cas9 genome editing tools to create variant p53 mutations in pluripotent stem cells (PSCs; e.g., iPSCs and ESCs) in order to explore the role of mutant p53 in osteosarcomagenesis. The Lee laboratory also works on modeling familial cancer syndromes with osteosarcoma predisposition by PSCs. Currently, the Lee laboratory applies whole genome sequencing, screening approaches and systems-level analyses to explore early genomic alterations and to understand dynamic alterations of the genomic landscape of LFS-associated osteosarcoma.
Dr. Lee’s research has been well recognized and published in journals as Cell, Cell Stem Cell, Molecular Cell, Cancer Cell, Cell Reports, Nature, Nature Cell Biology, Nature Protocols, Journal of Clinical Investigation, Trends in Cancer, and Trends in Biochemical Sciences.